These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19000475)

  • 21. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.
    Neff CP; Ndolo T; Tandon A; Habu Y; Akkina R
    PLoS One; 2010 Dec; 5(12):e15257. PubMed ID: 21203568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
    Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
    AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maraviroc for previously treated patients with R5 HIV-1 infection.
    Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
    N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
    Panos G; Watson DC
    Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus.
    Stephenson J
    JAMA; 2007 Apr; 297(14):1535-6. PubMed ID: 17426263
    [No Abstract]   [Full Text] [Related]  

  • 26. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
    Katlama C; Assoumou L; Valantin MA; Soulié C; Duvivier C; Chablais L; Kolta S; Pialoux G; Mercié P; Simon A; Costagliola D; Peytavin G; Marcelin AG;
    J Antimicrob Chemother; 2014 Jun; 69(6):1648-52. PubMed ID: 24535278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-HIV agents. New drugs, new hope, old lessons.
    TreatmentUpdate; 2007 Feb; 19(2):1-3. PubMed ID: 17447311
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of HIV infection with the CCR5 antagonist maraviroc.
    Kromdijk W; Huitema AD; Mulder JW
    Expert Opin Pharmacother; 2010 May; 11(7):1215-23. PubMed ID: 20402558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
    Andrews E; Glue P; Fang J; Crownover P; Tressler R; Damle B
    Br J Clin Pharmacol; 2010 Jan; 69(1):51-7. PubMed ID: 20078612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical pharmacology of antiretrovirals in development.
    Winston A; Mallon PW; Boffito M
    Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):447-58. PubMed ID: 16863445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two new drugs for HIV infection.
    Med Lett Drugs Ther; 2008 Jan; 50(1277):2-4. PubMed ID: 18197163
    [No Abstract]   [Full Text] [Related]  

  • 32. Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma.
    Pau AK; Penzak SR; Boyd SD; McLaughlin M; Morse CG
    Pharmacotherapy; 2012 Jan; 32(1):e1-6. PubMed ID: 22392831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new class of anti-HIV therapy and new challenges.
    Dolin R
    N Engl J Med; 2008 Oct; 359(14):1509-11. PubMed ID: 18832250
    [No Abstract]   [Full Text] [Related]  

  • 34. Off-label use of maraviroc in clinical practice.
    Blanco JR; Ochoa-Callejero L
    Expert Rev Anti Infect Ther; 2016; 14(1):5-8. PubMed ID: 26509356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
    Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
    AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [CCR5 antagonists: a new class of antiretrovirals].
    de la Tribonnière X; Yazdanpanah Y; Reynes J
    Med Mal Infect; 2008 Mar; 38 Suppl 1():S1-6. PubMed ID: 18455055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.
    Gulick RM; Fatkenheuer G; Burnside R; Hardy WD; Nelson MR; Goodrich J; Mukwaya G; Portsmouth S; Heera JR
    J Acquir Immune Defic Syndr; 2014 Jan; 65(1):78-81. PubMed ID: 24419064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
    Baroncelli S; Villani P; Weimer LE; Ladisa N; Francisci D; Tommasi C; Vullo V; Preziosi R; Cicalini S; Cusato M; Galluzzo C; Floridia M; Regazzi M;
    Ann Pharmacother; 2010 May; 44(5):838-43. PubMed ID: 20371753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When and how to use maraviroc in HIV-infected patients.
    Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM
    AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318
    [No Abstract]   [Full Text] [Related]  

  • 40. Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials.
    Moyle G; Rajicic N; Goodrich J; Mayer H; Valdez H
    AIDS; 2009 Jul; 23(12):1613. PubMed ID: 19622911
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.